| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial.
|
JAMA
|
2009
|
6.36
|
|
2
|
Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES.
|
J Am Coll Cardiol
|
2007
|
3.23
|
|
3
|
Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management.
|
Can J Cardiol
|
2006
|
3.20
|
|
4
|
6-min walk test provides prognostic utility comparable to cardiopulmonary exercise testing in ambulatory outpatients with systolic heart failure.
|
J Am Coll Cardiol
|
2012
|
3.03
|
|
5
|
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
|
Circulation
|
2004
|
2.73
|
|
6
|
Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials.
|
J Am Coll Cardiol
|
2002
|
2.19
|
|
7
|
Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
|
Circ Heart Fail
|
2011
|
1.93
|
|
8
|
Reproducibility of peak oxygen uptake and other cardiopulmonary exercise testing parameters in patients with heart failure (from the Heart Failure and A Controlled Trial Investigating Outcomes of exercise traiNing).
|
Am J Cardiol
|
2008
|
1.79
|
|
9
|
Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers.
|
Can J Cardiol
|
2007
|
1.70
|
|
10
|
Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial.
|
Circ Heart Fail
|
2012
|
1.54
|
|
11
|
Digoxin prescribing for heart failure in elderly residents of long-term care facilities.
|
Can J Cardiol
|
2005
|
1.46
|
|
12
|
Association between psychotropic drug use and heart failure therapy in elderly long-term care residents.
|
J Am Geriatr Soc
|
2006
|
1.38
|
|
13
|
Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM.
|
Eur J Heart Fail
|
2006
|
1.23
|
|
14
|
Heart failure and cognitive impairment: challenges and opportunities.
|
Clin Interv Aging
|
2007
|
1.18
|
|
15
|
Differences in sustainability of exercise and health-related quality of life outcomes following home or hospital-based cardiac rehabilitation.
|
Eur J Cardiovasc Prev Rehabil
|
2004
|
1.17
|
|
16
|
Screening for cognitive deficits using the Montreal cognitive assessment tool in outpatients ≥65 years of age with heart failure.
|
Am J Cardiol
|
2011
|
1.17
|
|
17
|
Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies.
|
Can J Cardiol
|
2008
|
1.15
|
|
18
|
Metabolic profile and exercise capacity outcomes: their relationship to overweight and obesity in a Canadian cardiac rehabilitation setting.
|
J Cardiopulm Rehabil
|
2005
|
1.09
|
|
19
|
Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
|
Am J Cardiol
|
2008
|
1.07
|
|
20
|
Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials.
|
Can J Cardiol
|
2009
|
1.04
|
|
21
|
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
|
Eur J Heart Fail
|
2005
|
1.04
|
|
22
|
Management of heart failure in Canadian long-term care facilities.
|
Can J Cardiol
|
2004
|
1.02
|
|
23
|
Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.
|
JAMA
|
2005
|
1.01
|
|
24
|
The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs.
|
Can J Cardiol
|
2010
|
1.00
|
|
25
|
Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure.
|
J Card Fail
|
2006
|
0.99
|
|
26
|
Cardiovascular aging and exercise in healthy older adults.
|
Clin J Sport Med
|
2008
|
0.95
|
|
27
|
Low-volume, high-intensity interval training in patients with CAD.
|
Med Sci Sports Exerc
|
2013
|
0.94
|
|
28
|
Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.
|
Circ Heart Fail
|
2012
|
0.94
|
|
29
|
Predicting heart failure mortality in frail seniors: comparing the NYHA functional classification with the Resident Assessment Instrument (RAI) 2.0.
|
Int J Cardiol
|
2011
|
0.92
|
|
30
|
Flow-mediated dilation is acutely improved after high-intensity interval exercise.
|
Med Sci Sports Exerc
|
2012
|
0.90
|
|
31
|
Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy.
|
Circ Heart Fail
|
2011
|
0.86
|
|
32
|
Cognitive function and self-care management in older patients with heart failure.
|
Eur J Cardiovasc Nurs
|
2013
|
0.86
|
|
33
|
Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both.
|
Am J Cardiol
|
2005
|
0.86
|
|
34
|
Effect of aerobic vs combined aerobic-strength training on 1-year, post-cardiac rehabilitation outcomes in women after a cardiac event.
|
J Rehabil Med
|
2007
|
0.85
|
|
35
|
Six-year follow-up of a randomised controlled trial examining hospital versus home-based exercise training after coronary artery bypass graft surgery.
|
Heart
|
2011
|
0.85
|
|
36
|
A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction.
|
Eur J Heart Fail
|
2014
|
0.84
|
|
37
|
ACE inhibitors in heart failure: what more do we need to know?
|
Am J Cardiovasc Drugs
|
2005
|
0.83
|
|
38
|
The Dutch Objective Burden Inventory: validity and reliability in a Canadian population of caregivers for people with heart failure.
|
Eur J Cardiovasc Nurs
|
2010
|
0.83
|
|
39
|
Heart rate recovery and heart rate variability are unchanged in patients with coronary artery disease following 12 weeks of high-intensity interval and moderate-intensity endurance exercise training.
|
Appl Physiol Nutr Metab
|
2013
|
0.82
|
|
40
|
The role of angiotensin II receptor blockers in the treatment of heart failure patients.
|
Congest Heart Fail
|
2003
|
0.81
|
|
41
|
The older patient with heart failure: high risk for frailty and cognitive impairment.
|
Expert Rev Cardiovasc Ther
|
2012
|
0.81
|
|
42
|
Living and dying with heart failure in long-term care: experiences of residents and their family members.
|
Int J Palliat Nurs
|
2013
|
0.80
|
|
43
|
Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker.
|
Ther Adv Cardiovasc Dis
|
2009
|
0.80
|
|
44
|
Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure.
|
Eur J Heart Fail
|
2008
|
0.80
|
|
45
|
Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
|
Eur J Heart Fail
|
2005
|
0.80
|
|
46
|
Clinical, demographic and functional characteristics associated with pharmacotherapy for heart failure in older home care clients: a retrospective, population-level, cross-sectional study.
|
Drugs Aging
|
2011
|
0.78
|
|
47
|
Necessary cautions when considering digoxin in heart failure.
|
CMAJ
|
2007
|
0.78
|
|
48
|
Heart failure--related mortality and hospitalization in the year following admission to a long-term care facility: the geriatric outcomes and longitudinal decline in heart failure (GOLD-HF) study.
|
J Card Fail
|
2013
|
0.77
|
|
49
|
Exercise and the heart failure patient: aerobic vs strength training--is there a need for both?
|
Prog Cardiovasc Nurs
|
2006
|
0.77
|
|
50
|
Growth hormone therapy in heart failure: where are we now?
|
Congest Heart Fail
|
2003
|
0.77
|
|
51
|
Valsartan plus captopril did not improve survival more than captopril alone after myocardial infarction.
|
ACP J Club
|
2004
|
0.76
|
|
52
|
Management considerations in the care of elderly heart failure patients in long-term care facilities.
|
Future Cardiol
|
2014
|
0.76
|
|
53
|
Monitoring the response to pharmacologic therapy in patients with stable chronic heart failure: is BNP or NT-proBNP a useful assessment tool?
|
Clin Biochem
|
2007
|
0.76
|
|
54
|
Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction.
|
Eur J Heart Fail
|
2014
|
0.76
|
|
55
|
Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve).
|
Eur J Heart Fail
|
2014
|
0.76
|
|
56
|
The Value of Admission Clinical Data for Diagnosing Heart Failure in Long-term Care.
|
Can Geriatr J
|
2013
|
0.75
|
|
57
|
The impact of an outpatient heart failure clinic on hospital costs and admissions.
|
Int J Health Care Qual Assur Inc Leadersh Health Serv
|
2004
|
0.75
|
|
58
|
Growth hormone therapy as a treatment for heart failure.
|
Evid Based Cardiovasc Med
|
2006
|
0.75
|
|
59
|
The effects of exercise training on insulin resistance in patients with coronary artery disease.
|
Eur J Cardiovasc Prev Rehabil
|
2007
|
0.75
|
|
60
|
Growth hormone therapy in heart failure: a novel therapy worthy of further consideration?
|
Expert Opin Investig Drugs
|
2005
|
0.75
|